Sodium tanshinone IIA sulfonate (STS) is a water soluble derivative of tanshinone IIa, which is the main lipophilic component contained in Salvia miltiorrhiza known as 'Danshen' in traditional Chinese medicine. The pharmacological activity of STS is due to tanshinone IIA, which is a cardioprotective substance and may exert a beneficial effect on the clinically important vascular endothelium.
Ion-Pair
1 mg/g (heart, lung and spleen homogenate, respectively).
Sample Preparation Seven hundred microliters of methanol was added to 300 ml of plasma sample. The obtained solution was vortexed for 10 min and centrifuged at 5000 rpm for 2 min to remove any protein and resultant supernatant was used in the assay. Tissue samples were weighed and placed into a hand-held glass micro-homogenizer with 1 ml of deionized water added, and then the tissues were crushed and grinded by mechanical force to form into tissue homogenate. Three hundred microliters of obtained respective tissue homogenate were assigned, and 700 ml of methanol was added to the obtained respective tissue homogenate in order to get rid of protein, and following performance were same treatment as plasma sample.
Specificity, Linearity, Limit of Detection (LOD) and Limit of Quantification (LOQ) To evaluate assay specificity, six independent lots of mouse blank plasma and respective tissue homogenates were analyzed in order to exclude the possibility of any co-eluting endogenous interference. Plasma and tissues homogenates calibration standards at concentrations over a range of 0.1 to 20 mg/ml were prepared and assayed in duplicate on five different days to demonstrate the linearity. Calibration curves of STS were constructed using the ratio of peak area of STS and concentration of STS standard by linear regression analysis. The limit of detection was defined as the lowest concentration of STS resulting in a peak area greater or equal to three times from background noise (S/NՆ3). The LOQ were investigated in plasma and tissues homogenates samples from five different days. For the determination of LOQ, the percentage deviation and %R.S.D. are to be less than 20%.
Assay Precision and Recovery
To evaluate precision, six QC replicates were prepared and analyzed at respective concentration for determining intra-day and inter-day validations, along with an independent calibration curve in each type of biological matrix for quantification. The intra-day precision was determined by analyzing 6 QC replicates in each type of tissue homogenate at concentrations of 0.1, 1 and 5 mg/ml (mg/g) for plasma and kidney, 0.1, 1 and 10 mg/g for liver, and 0.1, 0.5 and 1 mg/g for heart, spleen and lung, respectively prepared within a day. The inter-day precision was determined by analyzing the QC replicates prepared on six different days. The variability was expressed as the coefficient of variation (%CV) which should be Յ15% at all the concentrations except LOQ whose value should not more than 20%. To determine absolute recovery of STS, the plasma and tissue samples were spiked with STS to achieve six replicates at respective concentration ranging from 0.1 to 10 mg/ml (mg/g), and were then extracted with methanol, respectively. The six replicates were analyzed in various type of biological specimens for respective concentration on three different days. The recovery was calculated by comparing analyte peak areas of the extracted samples with that of STS standard solution at the same nominal concentrations.
Pharmacokinetics and Biodistribution Study of STS Kunming male mice (19-22 g) were administered STS at a dose of 50 mg/kg via the tail vein. The mice were then sacrificed at 1, 5, 10, 15, 20 min, 0.5, 1, 2, 4, 8, 12 and 24 h after injection. The plasma and tissues samples were rapidly collected, and all the samples were stored at Ϫ20°C until analysis of STS, as described above. The concentration data, at each time point, represented the Vol. 55, No. 5 
Results and Discussion
Method Validation The chromatograms of STS spiked in mouse plasma and blank mouse plasma were shown in previous reports.
10) The representative chromatograms of STS spiked in mouse tissues (A) and the blank mouse tissues (B) are shown Fig. 2 .
The retention time of STS was 7.5 min. There was good baseline separation of STS and major components from mouse tissue samples. No endogenous or extraneous peaks were observed interfering with separation and quantification of STS. STS was stable during the time of analysis and no degradation products were found using the above-mentioned mobile phase. The linear regression equations for STS in mouse plasma and tissues are shown in Table 1 . A linear relation was found between peak area and STS concentrations within the ranges of 0.1-5 mg/ml for plasma, 0.1-5 mg/g of tissue for kidney homogenate, 0.1-20 mg/g of tissue for liver homogenate, 0.1-1 mg/g of tissue for heart, spleen and lung homogenates, respectively. In the mouse plasma and tissues, the limit of quantification (LOQ) and the limit of detection (LOD) for STS were 100 ng/ml and 20 ng/ml.
The average precision rate for all the biological specimens are listed in Table 1 . Over the range of STS tested, average inter-and intra-day precision of STS in these biological samples were within 4.9%, indicating a highly reproducible and robust assay. The average recoveries of STS after the extraction procedure are listed in Table 2 . The recovery of this method was more than 92% at all concentration levels in each type of biological specimens on different days. The multi-day experiment also showed that the recovery of this method kept stable over 6 d.
It is known to all that the quality of bioanalytical methods will often be highly improved using an internal standard, which partly compensates inaccuracies in sample preparation, recovery, and chromatography. Because of the high and stable recovery of this method, we thought that there is no need to implement an internal standard.
Plasma Pharmacokinetics Figure 3 illustrates the plasma STS concentration-time profile after a intravenous dose of 50 mg/kg. STS plasma concentration-time data were best fitted with a two-compartment model, characterized by an initial rapid phase of drug concentration decrease, and a slower terminal elimination phase. At 4 h, the plasma concentrations were below 20 ng/ml. The pharmacokinetic parameters are shown in Table 3 . The pharmacokinetics of STS was characterized with a distribution half-life (t 1/2a ) of 1.2Ϯ0.18 min, a terminal half-life (t 1/2b ) of 21.6Ϯ2.4 min, a distribution volume (V) of 0.057Ϯ0.011 l/kg, a plasma clearance (CL) of 0.86Ϯ0.12 l/h/kg and an AUC 0-∞ of 58.41Ϯ 6.21 mg · h/ml.
Tissue Distributions The distribution characteristics of STS to the various tissues are presented in Fig. 4 . STS was widely distributed into most tissues after i.v. administration. The highest STS concentration was found in the liver. In liver, STS concentrations were maximal at 5 min after drug administration and declined progressively during 30 min, and decreased quickly with the time thereafter. STS could be determined at 12 h and 4 h after drug administration in liver and kidney, respectively. STS was hardly detected at 2 h after drug administration in the other tissues. In heart, STS concentrations were unaltered during 10 min, and declined fast after this. At 10 min after administration of STS, the highest STS concentration was found in kidney>lung>heart>spleen. This result suggested that STS was mainly cleared via both liver and kidney. Urine may be one of considerable excretion pathway for STS because of a relatively high STS concentrations in kidney. STS concentrations in heart, as compared with in other tissues, was not high at various time point in spite of STS as a cardiovascular drug. A dramatic concentration of STS in liver indicated that STS may be applied to treat liver disease such as chronic hepatitis, cirrhosis and hepatoma considering its extensive pharmacological activity. In fact, a few researches have demonstrated a promising potential of STS to treat liver disease. [11] [12] [13] In addition, a new chromatographic peak, which has a retention time of 2 min was determined for the first time in liver during 2 h after administration of STS injection. We presumed that the new compound may be one of STS metabolite, which may be more hydrophilic than STS. STS was metabolized not only with its original form but also with other form such as adding hydrophilic group.
Conclusion
In conclusion, we have developed and validated the ionpair RP-HPLC method for the determination of STS in various biological samples. The method showed great linearity and had a high degree of selectivity, sensitivity, precision and recovery. We reported for the first time that pharmacokinetics and biodistribution characteristics of intravenously administrated STS in mice by using the validated HPLC method. STS was rapidly cleared from the circulation with a short half-life. STS was widely distributed into most tissues and was obviously accumulated in liver, which indicated that STS may be promising to treat liver disease. Urine may be one of considerable excretion pathway for STS. 
